Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P36P | ISIN: US55234L1052 | Ticker-Symbol:
NASDAQ
01.04.25
21:23 Uhr
0,123 US-Dollar
-0,004
-2,76 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
LYRA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
LYRA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur LYRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.03.Lyra Therapeutics GAAP EPS of -$1.43 misses by $0.10, revenue of $1.53M1
LYRA THERAPEUTICS Aktie jetzt für 0€ handeln
13.03.Lyra Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
13.03.Lyra Therapeutics, Inc. - 10-K, Annual Report3
13.03.Lyra Therapeutics, Inc. - 8-K, Current Report1
13.03.Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update374Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities...
► Artikel lesen
10.01.Lyra Therapeutics, Inc. - 8-K, Current Report6
13.12.24Lyra Therapeutics, Inc. - 8-K, Current Report4
13.11.24Lyra Therapeutics GAAP EPS of -$0.18 beats by $0.02, revenue of $0.2M misses by $0.06M3
12.11.24Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update152Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension...
► Artikel lesen
12.11.24Lyra Therapeutics, Inc. - 10-Q, Quarterly Report-
12.11.24Lyra Therapeutics, Inc. - 8-K, Current Report-
15.10.24Lyra Therapeutics schließt Patientenrekrutierung für Phase-3-Studie zur CRS-Behandlung ab5
15.10.24Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis143-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company...
► Artikel lesen
14.08.24Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update183- Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned - - In parallel...
► Artikel lesen
06.05.24Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis267ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA)...
► Artikel lesen
30.04.24Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update201WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory...
► Artikel lesen
26.04.24Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)311WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the "Company" or "Lyra"), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1